Currently, there are 365.24M common shares owned by the public and among those 356.87M shares have been available to trade.
The company’s stock has a 5-day price change of 6.74% and 32.47% over the past three months. BHC shares are trading 14.46% year to date (YTD), with the 12-month market performance down to -4.08% lower. It has a 12-month low price of $5.57 and touched a high of $10.15 over the same period. BHC has an average intraday trading volume of 2.17 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.55%, 13.13%, and 15.74% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Bausch Health Companies Inc (NYSE: BHC) shares accounts for 79.17% of the company’s 365.24M shares outstanding.
It has a market capitalization of $3.35B and a beta (3y monthly) value of 0.82. The earnings-per-share (ttm) stands at -$1.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.08% over the week and 3.53% over the month.
Analysts forecast that Bausch Health Companies Inc (BHC) will achieve an EPS of $0.69 for the current quarter, $0.91 for the next quarter and $3.87 for 2025. The lowest estimate earnings-per-share for the quarter is $0.51 while analysts give the company a high EPS estimate of $0.82. Comparatively, EPS for the current quarter was $0.52 a year ago. Earnings per share for the fiscal year are expected to increase by 10.93%, and 0.70% over the next financial year. EPS should shrink at an annualized rate of 2.60% over the next five years, compared to 32.76% over the past 5-year period.
Looking at the support for the BHC, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on September 20, 2023, with the firm’s price target at $9-$16. Truist was of a view on July 29, 2022 that the stock is Hold, while RBC Capital Mkts gave the stock Sector Perform rating on July 29, 2022, issuing a price target of $12- $5. JP Morgan on their part issued Neutral rating on July 28, 2022.
